Abstract:Diabetes, a chronic disease caused by genetic and environmental factors, threats the health of millions of people, which has become a global challenge. Therefore, much earlier intervention is required to prevent diabetes, type-2 diabetes particularly. Previous study revealed that glucagon-like peptide-1 is an intestine-derived insulinotropic hormone that stimulated glucose dependent insulin production and secretion from pancreatic 3-cells. Glucagon-like peptide-1 also exerted cytoprotective and antiapoptotic effects on 13-cells and decreased postprandial blood glucose via complicated mechanisms. However, glucagon-like peptide-1 was rapidly degraded and inactivated in vivo by the serine protease dipeptidyl peptidase4, which limited their ability to normalize blood glucose levels. Therefore, dipeptidyl peptidase-4 inhibitors could decrease the high levels of blood glucose in type 2 diabetes patients. In recent years, we have focused on synthesizing and evaluating the biological activities of novel xanthone compounds. Compound 9, a small xanthone derivative, was identified to show good dipeptidyl peptidase-4 inhibitory activity from high throughput screening (HTS) through varieties of xanthone derivatives and IC50 value against dipeptidyl peptidase-4 is 7.3 μg/mL (Fig. 1). Molecular docking study showed compound 9 could bind with the target enzyme and a pocket existed between the 7-substitued group and the target enzyme, which revealed that an adequate modification to compound 9 could Synthesis and Evaluation of Novel Xanthone Derivatives as Potent Dipeptidyl Peptidase-4 Inhibitors

Seco-prolinenitrile Inhibitors of Dipeptidyl Peptidase IV Define Minimal Pharmacophore Requirements at P1.

Design, Synthesis and Biological Evaluation of Novel Pyrimidinedione Derivatives As DPP-4 Inhibitors.

Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability: Interplay Between the N-terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of Alpha-Aminoacyl-l-cis-4,5-methanoprolinenitrile-based Inhibitors.

Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: identification of dipeptide derived leads

Design, Synthesis and Biological Evaluation of Novel Imidazolone Derivatives As Dipeptidyl Peptidase 4 Inhibitors.

Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors

Design, synthesis, biological evaluation, and docking studies of (s)-phenylalanine derivatives with a 2-cyanopyrrolidine moiety as potent dipeptidyl peptidase 4 inhibitors.

Discovering novel α-aminoacyl-containing proline derivatives with potent and selective inhibitory activity against dipeptidyl peptidase IV: design, synthesis, biological evaluation, and molecular modeling.

Recent Advances in Non-Peptidomimetic Dipeptidyl Peptidase 4 Inhibitors: Medicinal Chemistry and Preclinical Aspects

Discovery of tight-binding competitive inhibitors of dipeptidyl peptidase IV

Synthesis of phenylpyridine derivatives and their biological evaluation toward dipeptidyl peptidase-4

Synthesis and Biological Evaluation of Novel Benzyl-Substituted (S)-Phenylalanine Derivatives As Potent Dipeptidyl Peptidase 4 Inhibitors.

Synthesis and Evaluation of Novel Xanthone Derivatives As Potent Dipeptidyl Peptidase-4 Inhibitors

(R)-3-amino-1-((3as,7as)-octahydro-1h-indol-1-yl)-4-(2,4,5-trifluorophenyl)butan-1-one Derivatives As Potent Inhibitors of Dipeptidyl Peptidase-4: Design, Synthesis, Biological Evaluation, and Molecular Modeling.

Design, synthesis, structure-activity relationships, and docking studies of 1-(γ-1,2,3-triazol substituted prolyl)-(S)-3,3-difluoropyrrolidines as a novel series of potent and selective dipeptidyl peptidase-4 inhibitors.

Design, Synthesis, And Pharmacological Evaluation Of Highly Potent And Selective Dipeptidyl Peptidase-4 Inhibitors

Synthesis, structure-activity relationship, and pharmacophore modeling studies of pyrazole-3-carbohydrazone derivatives as dipeptidyl peptidase IV inhibitors.

Synthesis and Biological Evaluation of Pyrrolidine-2-carbonitrile and 4-Fluoropyrrolidine-2-carbonitrile Derivatives As Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes.

Design, Synthesis and Biological Evaluation of 4-Fluoropyrrolidine-2-carbonitrile and Octahydrocyclopenta[b]pyrrole-2-carbonitrile Derivatives As Dipeptidyl Peptidase IV Inhibitors.

Molecular Mechanistic Insights into Dipeptidyl Peptidase-IV Inhibitory Peptides to Decipher the Structural Basis of Activity

Synthesis, Biological Evaluation and Molecular Docking of (R)‐2‐((8‐(3‐aminopiperidin‐1‐yl)‐3‐methyl‐7‐(3‐methylbut‐2‐en‐1‐yl)‐2,6‐dioxo‐2,3,6,7‐tetrahydro‐1H‐purin‐1‐yl)methyl)benzonitrile as Dipeptidyl Peptidase IV Inhibitors